Compugen Q1 FY26 net loss widens to USD 7.7 million; revenue slips to USD 2.2 million

• Compugen posted a Q1 net loss of USD 7.7 million, or USD 0.08 per share, versus a net loss of USD 7.2 million, or USD 0.08 per share, a year earlier.
• Revenue edged down to USD 2.2 million from USD 2.3 million, reflecting recognition of portions of the upfront payment and the IND milestone payment under its Gilead license agreement.
• R&D expenses climbed to USD 6.9 million from USD 5.8 million, due to higher clinical spending for the MAIA-ovarian trial and drug supply costs.
• Cash and cash equivalents, short-term bank deposits, and marketable securities totaled USD 134.9 million as of March 31, with cash runway expected to fund operations into 2029.
• The COM701 MAIA-ovarian trial is actively enrolling across sites in the U.S., Israel and France, with interim analysis on track by Q1 2027; AstraZeneca is advancing rilvegostomig across 11 Phase 3 trials, while the Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60723) on May 18, 2026, and is solely responsible for the information contained therein.